A single‐center review of outcomes between COVID‐19 vaccinated and unvaccinated liver transplant recipients
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15185 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Annelise Nolan and 6 co-authors. Institution: Wexner Medical Center, Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA. Major MEDLINE topics: COVID-19, Liver Transplantation. Cited 1 times so far (Crossref); 12 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
With the availability of vaccines against SARS‐COV‐2, recommendations for vaccination of transplant candidates are widespread. At our institution, patients may receive liver transplant (LTx) regardless of vaccine status. The purpose of this study is to compare post‐LTx outcomes between vaccinated (VAX) and unvaccinated (UNVAX) LTx recipients.
Methods
This is a retrospective, single‐center study of LTx from January 1, 2021–March 30, 2022. The primary outcome is incidence of post‐LTx COVID‐19. Secondary outcomes include graft function, mortality, graft loss, and COVID‐19 treatment.
Results
One hundred and seventy‐seven LTx recipients were included, 57% [101/177] VAX and 43% [76/177] UNVAX. Baseline characteristics were similar between groups. Overall, 28 (36.8%) UNVAX and 34 (33.7%) VAX tested COVID‐19 positive during the study period ( p = .193) at a mean of 312.6 [255.4–369.8] days for UNVAX versus 254.6 [215.2–293.9] days for VAX ( p = .084). COVID‐19 treatment was administered in 15 (53.6%) of the UNVAX compared to 22 (64.7%) in the VAX ( p = .374), although eight (28.6%) of UNVAX required hospital admission for treatment compared with two (5.9%) of VAX ( p = .016). There were no statistically significant differences in death, and no COVID‐19 related death or graft loss. There were no statistically significant differences in liver function tests at 3‐ and 12‐months post LTx.
Conclusion
In a series with a large percentage of UNVAX patients, LTx appears to be safe, with no difference in the rate of COVID‐19 or transplant‐related outcomes compared to VAX. While we encourage vaccination to prevent severe COVID, based on our results, vaccine status should not be reason to deny lifesaving transplant.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Wexner Medical Center, Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
- The Ohio State University College of Pharmacy, Columbus, Ohio, USA.
- Division of Nephrology, The Ohio State University, Columbus, Ohio, USA.
- Division of Nephrology and Comprehensive Transplant Center, The Ohio State University, Columbus, Ohio, USA.
ORCID profiles: Annelise Nolan, Priyamvada Singh
Cite
APA
Nolan, A., McGowan, M., Von Stein, L., Ross, A., Kaur, M., Pesavento, T., & Singh, P. (2024). A single‐center review of outcomes between COVID‐19 vaccinated and unvaccinated liver transplant recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15185
Vancouver
Nolan A, McGowan M, Von Stein L, Ross A, Kaur M, Pesavento T, et al. A single‐center review of outcomes between COVID‐19 vaccinated and unvaccinated liver transplant recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.15185
BibTeX
@article{Nolan2024,
author = {Nolan, Annelise and McGowan, Melissa and Von Stein, Lauren and Ross, Adrienne and Kaur, Manjit and Pesavento, Todd and Singh, Priyamvada},
title = {A single‐center review of outcomes between COVID‐19 vaccinated and unvaccinated liver transplant recipients},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15185}
}
EUVIMED